Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMast Energy. Regulatory News (MAST)

Share Price Information for Mast Energy. (MAST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.19
Bid: 0.18
Ask: 0.20
Change: 0.00 (0.00%)
Spread: 0.02 (11.111%)
Open: 0.19
High: 0.19
Low: 0.19
Prev. Close: 0.19
MAST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pyebridge Trading and Operational Update

5 Jul 2022 07:00

RNS Number : 2727R
Mast Energy Developments PLC
05 July 2022
 

Mast Energy Developments PLC

(Incorporated in England and Wales)

(Registration Number: 12886458)

Share code on the LSE: MAST

ISIN: GB00BMBSCV12

("MED" or "the Company")

 

5 July 2022

Mast Energy Developments Plc ("MED" or "the Company")

 

 Pyebridge Trading and Operational Update

 

Mast Energy Developments Plc, the UK-based multi-asset owner and operator in the rapidly growing Reserve Power market is pleased to announce an update with regards to its current flagship producing asset, the 9 MW Pyebridge Synchronous Gas-powered Standby Generation Facility (the "Site" or "Pyebridge") that was acquired in August 2021 (see RNS dated 12 August 2021).

 

Since the Site commenced with steady state production it has provided MED with an opportunity to assess, identify and address further areas where operational efficiencies could be achieved. The additional operational improvements also provided the opportunity to enhance key metrics of the Power Purchase Agreement ("PPA") Pyebridge has with Statkraft, that resulted in a further enhancement of the Pyebridge economics and profitability. (Also see RNS dated 15 November 2021)

 

An overview of the key highlights with regards to the Site's actual performance both operationally and economically is provided below.

 

Trading Update

 

The Pyebridge Site generated the following actual performance figures for the 3-month period March to May 2022:

· Power Sales Revenue Turnover - c. £130,000

· Total Electricity Generation Output - c. 371 MWh

· Average Power Sales Price achieved per MWh sold - c. £354

 

The average power sales price per MWh achieved during the 3-month period March to May 2022 of c. £354 is around 5x higher than the average power sales price at the time of MED's IPO in April 2021 (i.e. around £66). Although the associated generation gas cost also increased during this time, there is a positive net variance that will add to the Site's profitability.

 

The above actual performance figures pre-date the finalisation of the operational and PPA enhancements and optimisations referred to below. MED expects that the actual performance of the Site for the period post finalisation of such optimisation will result in a net operational profit margin of c. 30%, which is currently being independently confirmed by EnAppSys as part of their financial remodelling of Pyebridge referred to below.

 

 

 

Operational Optimisation

 

The following operational efficiencies were identified and addressed:

· The Pyebridge site's gas connection license class was upgraded from a Class 1 AQ to a Class 2 AQ (the best and most cost effective available) following the requisite gas usage proof period to allow the class change appeal application, which results in a significant increase in the site's operational profit margin, due to a significant decrease in gas usage costs associated to the new gas AQ license;

· Each of the Site's three engines' bursting discs were replaced with re-settable bursting discs, which results in a significant decrease in engine availability downtime and increase in revenue generation potential;

· Reduction of ongoing costs associated with the inherent own electricity consumption and heating of the engines;

· Optimisation of the Operations & Maintenance ("O&M") contract terms with a focus on performance and reducing the variable O&M cost per MW; and

· Limitation of the number of engine starts, by refining and enhancing the Warranted Operational Parameters in the PPA with the off-taker, Statkraft (see details in the section below), which contributes to the engines achieving higher net generation output efficiencies and running more profitable.

Enhancing Commercial Aspects of the PPA

 

The initial period of steady state operations, allowed MED to enhance the following Warranted Operational Parameters in the PPA with the off-taker:

 

· Increased electricity generation output efficiencies of the engines;

· Increased minimum profit trade starts threshold;

· Increased number of available hours to run per annum to 4,000 hours (up from 2,500 hours); and

· Reduction of the variable O&M cost per MW in line with the revised O&M contract.

 

Impact of Optimisation on Economics

MED is in the process of updating the Pyebridge Financial Model with its leading independent UK energy market data provider, EnAppSys in order to confirm the positive impact of the various operational and PPA enhancements. It is expected that the site operational and PPA enhancements will have a significant positive impact on the Site's economics.

 

Pieter Krügel, MED CEO, commented: "We are pleased to report Pyebridge's maiden operational trading results. The past few months have been used fruitfully and provided the MED management and operational teams the opportunity to further optimise and enhance the Site's performance. We are looking forward to providing investors with a further update on Pyebridge in due course.

Rapidly rising costs of living in the UK driven by energy inflation have increased the need for locally produced energy at competitive rates. The recent Winter 22/23 contracts entered into by UK Government with coal fuelled electricity generating counterparties have further underlined the strategic and economic challenges currently dominating GB power markets. There is an increasingly strategic and valuable need to provide dependable back-up distributed generation to help support the large-scale renewable energy projects coming on stream and mitigate any resultant market volatility of intermittency in low carbon generation.

In such an uncertain geopolitical and macroeconomic environment, the management of MED continues to believe that flexible capacity will play a key role in delivering the necessary Net Zero transition in GB markets over the coming years, while keeping prices as low as possible. Consequently, management continues to explore new potential flexible power sites and assets in the current market. Management will closely evaluate any such opportunities to build a selective pipeline of operating & development assets that could provide the greatest potential for value creation for its shareholders."

 

ENDS

This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

 

For further information please visit www.med.energy or contact:

 

 Pieter Krügel

info@med.energy

Mast Energy Developments Plc

CEO

 Jonathan Critchley & Keith Swann

+44 (0)20 3869 6080

Clear Capital Markets

Joint Broker

 Chris Hardie & Sarah Mather

+44 (0)20 7220 1666

WH Ireland Limited

Joint Broker

 Zainab Slemang van Rijmenant

zainab@lifacommunications.com

Lifa Communications

Investor and Media

Relations Advisor

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUSUNRUKUBRAR
Date   Source Headline
30th May 20242:00 pmRNSResult of AGM
29th May 20249:11 amRNSHolding(s) in Company
23rd May 20243:55 pmRNSCapitalisation of Loan Update
21st May 20247:00 amRNSBusiness Update
9th May 202410:45 amRNSHolding(s) in Company
8th May 20247:00 amRNSNotice of AGM
7th May 20247:00 amRNSUpdate, Loan Capitalisation & Equity Issue
30th Apr 20247:00 amRNSResults for the year ended 31 December 2023
26th Apr 20247:00 amRNSBusiness Update
23rd Apr 20242:30 pmRNSHolding(s) in Company TR 1
11th Apr 20247:00 amRNSBusiness Update
7th Mar 20248:06 amRNSQ1 2024 Corporate Presentation
4th Mar 202410:45 amRNSHolding(s) in Company
28th Feb 20247:00 amRNSFunding Partner, Agreement & Proventure Terminated
20th Feb 20241:00 pmRNSTR-1: Standard form notification of major holdings
5th Feb 20241:55 pmRNSTR-1: Standard form notification of major holdings
24th Jan 20243:45 pmRNSHolding(s) in Company
8th Jan 20247:00 amRNSMED Binding JVA Progress Update
2nd Jan 20247:00 amRNSMED Binding JVA Completion Update
22nd Dec 20237:00 amRNSMED Binding JVA Completion Update
15th Dec 20237:00 amRNSDirector Loan & PDMR Share Sale
11th Dec 20237:52 amRNSMED Binding JVA Update
11th Dec 20237:00 amRNSMED Binding JVA Completion Update
5th Dec 20234:30 pmRNSHolding(s) in Company
1st Dec 20237:00 amRNSMED Binding JVA Completion Update
15th Nov 20233:31 pmRNSDirector/PDMR Shareholding
13th Nov 20237:00 amRNSMED Binding JVA Interim Payment Update
26th Oct 202310:54 amRNSHolding(s) in Company
23rd Oct 20237:00 amRNSMED Binding JVA Completion Update
12th Oct 20232:03 pmRNSHolding(s) in Company
12th Oct 20232:01 pmRNSHolding(s) in Company
12th Oct 20232:00 pmRNSHolding(s) in Company
5th Oct 20237:00 amRNSIssue of Equity
22nd Sep 20237:00 amRNSMED Binding JVA Completion Update
1st Sep 20237:00 amRNSMED Binding Joint Venture Completion Update
25th Aug 20237:00 amRNSHalf-year Report
9th Aug 20232:16 pmRNSHolding(s) in Company
4th Aug 20237:00 amRNSMED Binding Joint Venture Completion Update
12th Jul 20231:15 pmRNSJoint Venture
6th Jun 20231:09 pmRNSResult of AGM
23rd May 20232:30 pmRNSIssue of Equity
22nd May 20233:00 pmRNSShares issue
18th May 20237:00 amRNSJV & Investment. New Broker & Loan Reprofiling
16th May 20231:15 pmRNSNotice of AGM
4th May 20237:00 amRNSQ1 Corporate Presentation and Website Update
28th Apr 20237:00 amRNSResults for the year ended 31 December 2022
27th Feb 20237:00 amRNSPyebridge Update
20th Dec 20224:40 pmRNSSecond Price Monitoring Extn
20th Dec 20224:35 pmRNSPrice Monitoring Extension
20th Dec 20222:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.